Central Venous Catheter Market to be driven by expansion of healthcare facilities globally and the increasing investments in healthcare infrastructure is expected to grow at a CAGR of 5.60% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published the latest research report on the “Global Central Venous Catheter Market” that contains information from 2018 to 2032. The Central Venous Catheter market is estimated to register a CAGR of 5.60% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Central Venous Catheter market— Amecath, B. Braun Melsungen AG, Boston Scientific Corporation, AngioDynamics, Inc., BACTIGUARD, Cook Medical, Inc., Smiths Medical, Becton, Dickinson & Company, Biosensors International Group Ltd., BARD Care, ConMed Corporation, Edwards Lifesciences Corporation, and Coloplast.

Central Venous Catheter Market Highlights

The global Central Venous Catheter market is accounted to register a CAGR of 5.60% during the forecast period and is estimated to reach USD 1.959 billion by 2032.

A rising number of people are developing chronic illnesses, which is driving the central venous catheter market's CAGR. Central venous catheters (CVCs) are widely used in modern healthcare due in large part to the rising incidence of chronic illnesses, especially cancer and cardiovascular diseases. These catheters are necessary to deliver efficient, continuous care to patients with these challenging conditions. For patients undergoing long-term care, CVCs are essential because they simplify the administration of critical medications, blood transfusions, and fluid therapy. As the worldwide burden of chronic diseases increases, so does the need for central venous catheters in providing precise and continuous medical interventions. This underscores the catheters' critical role in enhancing patient care and treatment outcomes in the face of challenging medical circumstances.

Segment Analysis

The global Central Venous Catheter market has been segmented based on Product Type, Property, Design, and Compositions

Based on Product Type, the global Central Venous Catheter market has been segmented into Non-tunneled Catheters and tunneled Catheters. The Non-tunneled Catheters segment was expected to hold the largest market share in 2022. The overall growth of this segment is being driven by the rise in incisions worldwide and the increasing recognition of the need to use non-tunneled catheters during emergencies.

Based on Property, the global Central Venous Catheter market has been segmented into Antimicrobial Catheters, Non-Antimicrobial Catheters, and Others. The Antimicrobial Catheters segment was anticipated to hold the major market share in 2022. A worldwide focus on preventing HAIs (Healthcare-Associated Infections) is driving market expansion in this region.

Based on Design, the global Central Venous Catheter market has been segmented into Multi Lumen, Double Lumen, and Single Lumen. The double-lumen segment was expected to hold the biggest market share in 2022. The increase in ICU treatments for ARF (acute renal failure) is driving the growth of the market overall in this region.

Based on Compositions, the global Central Venous Catheter market has been segmented into Polyurethane, Silicone, and Others. The Silicon segment was anticipated to hold the major market share in 2022. Due to their flexibility and extended lifespan when used as tunneled central venous catheters (CVCs), silicone catheters are the recommended choice across the globe.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Central Venous Catheter Market Research Report

Regional Analysis

The global Central Venous Catheter market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Central Venous Catheter market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Central Venous Catheter market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Central Venous Catheter market comprises of Middle East, Africa, and Latin America.

The largest market share for Central Venous Catheters was maintained by the North American regional sector. This is because the area has a high prevalence of chronic diseases like cancer and kidney issues, prominent people live there, and the number of critically ill patients is rising.

Moreover, the Europe market has been persistently growing over the forecast period. The aging population's rising need for sophisticated medical treatments, such as CVCs for chronic illnesses like cancer and heart disease, is driving the market.

Additionally, the Asia-Pacific Central Venous Catheter Market is anticipated to expand at the quickest rate. The high frequency of chronic illnesses, the increase in affordability, and the expansion of healthcare access in developing countries are the main drivers of the market's growth in the region. Furthermore, in the Asia-Pacific area, the Indian Central Venous Catheter market was expanding at the fastest rate, while China's market had the biggest market share.

Furthermore, the rest of the world's Central Venous Catheter market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the growing prevalence of chronic diseases and the expanding number of surgical interventions.

Key Findings of the Study

• The global Central Venous Catheter market is expected to reach USD 1.959 billion by 2032, at a CAGR of 5.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the growing prevalence of chronic diseases and the expanding number of surgical interventions.


• Based on Product Type, the Non-tunneled Catheters segment was attributed to holding the largest market in 2022, with an approximate market share of 47%.


• Amecath, B. Braun Melsungen AG, Boston Scientific Corporation, AngioDynamics, Inc., BACTIGUARD, Cook Medical, Inc., Smiths Medical, Becton, Dickinson & Company, Biosensors International Group Ltd., BARD Care, ConMed Corporation, Edwards Lifesciences Corporation, and Coloplast.